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license (http://creativelayers in eyes of patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD)
with paired control eyes using optical coherence tomography.
Methods: Sixty-three eyes of 34 subjects, 12 eyes with AD and 51 eyes with MCI, positive to 11C-
labeled Pittsburgh Compound-B with positron emission tomography (11C-PiB PET/CT), and the same
numberof sex- and age-paired control eyesunderwent optical coherence tomography scanning analyzing
retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), Bruch’s membrane opening–minimum rim
width (BMO-MRW), inner plexiform layer (IPL), outer nuclear layer, and lamina cribrosa (LC).
Results: Compared with healthy controls, eyes of patients with positive 11C-PiB PET/CT showed a
significant thinning of RNFL (P , .028) and GCL (P , .014). IPL and outer nuclear layer also
showed significant thinning in two (P , .025) and one location (P , .010), respectively. No sig-
nificant differences were found when optic nerve measurements BMO-MRW and LC were
compared (P . .131 and P . .721, respectively). Temporal sector GCL, average RNFL, and tem-
poral sector RNFL also exhibited significant thinning when MCI and control eyes were compared
(P 5 .015, P 5 .005 and P 5 .050, respectively), and also the greatest area under the curve values
(0.689, 0.647, and 0.659, respectively). GCL, IPL, and RNFL tend to be thinner in the AD group
compared with healthy controls.
Discussion: Our study suggests that RNFL and GCL are useful for potential screening in the early
diagnosis of AD. LC and BMO-MRW appear not to be affected by AD.
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Alzheimer’s disease (AD) is a complex neurodegenera-
tive disorder and the leading cause of dementia [1]. Well-
known neuropathological hallmarks of AD are intracellular
neurofibrillary tangles of hyperphosphorylated tau protein
(p-Tau) and extracellular amyloid b (Ab) protein deposits
throughout the brain, which distinctly contribute to a defin-
itive diagnosis of AD [2]. These neuropathological changes
are believed to develop 15–20 years before the onset of clin-
ical dementia [3]. Mild cognitive impairment (MCI) is the
prodromal phase of AD, during which objective cognitive
problems but no functional impairment are observed [4].
Different in vivo biomarkers have been studied in the early
diagnosis of AD [4], leading to the incorporation of three
core cerebrospinal fluid (CSF) biomarkers for AD into mod-
ern diagnostic research criteria: the 42–amino acid form of
Ab (Ab42), total tau (T-tau), and phosphorylated tau (P-
tau) [5]. Ab pathology is detected by decreased Ab levels
in CSF or with positron emission tomography/computed to-
mography (PET/CT) imaging using 11C-labeled Pittsburgh
Compound-B (11C-PiB) ligand [3], whereas neuronal injury
is reflected by either cortical atrophy on magnetic resonance
imaging (MRI), hypometabolism on fluorodeoxyglucose-
PET/CT (FDG-PET/CT), and other amyloid PET radio-
tracers, or increased T-tau and/or p-Tau levels in CSF
[6,7]. Nevertheless, current diagnostic modalities for AD
are restricted by standardization problems and invasiveness
in the case of CSF markers, and high costs and limited
availability in the case of amyloid PET [8,9]. These factors
have prompted the investigation of cheaper and less-
invasive AD biomarkers.
It has long been recognized that patients with early AD
showed visual function impairments [10]. Moreover, several
studies using optical coherence tomography (OCT) [11–17]
to analyze different eye structures have reported retinal and
optic nerve changes in patients with AD andMCI. Studies in
patients with AD have shown retinal nerve fiber layer
(RNFL) thinning [11–17], retinal ganglion cell layer
(GCL) degeneration [12,15], choroidal thickness changes,
and vascular alterations. However, the diagnosis of AD in
nearly all studies was made using the Mini–Mental State Ex-
amination and was not supported with biomarkers, which
might imply a variable degree of case misclassification,
affecting statistical power and the interpretation of results.
Lamina cribrosa (LC) has been studied in other neurode-
generative diseases, including Parkinson’s disease [18], but
until now, LC has not been measured in AD. Similarly, Bru-
ch’s membrane opening–minimum rim width (BMO-MRW)
has not been previously measured in patients with AD. This
parameter measures the neuroretinal rim from the BMO to
the nearest point on the internal limiting membrane, and
the shortest distance constitutes a measurement that reduces
interindividual variation, while providing higher sensitivity
and specificity compared with RNFL in patients with glau-
coma [19].The aim of this study was to assess anatomic variations in
the optic nerve and retina of amyloid-positive patients
defined by 11C-PiB PET/CT and in age- and gender-
matched healthy controls (HCs), using OCT analyses,
including RNFL, GCL, LC, and BMO-MRW, for a better un-
derstanding of the damage this disease causes in the eye, and
to determine the best OCT biomarkers in patients with AD
and prodromal MCI. To the best of our knowledge, this
might be the first report that analyzes OCT changes in indi-
viduals with cognitive impairment and positive 11C-PiB
PET/CT, and LC and BMO-MRW in patients with AD.2. Methods
2.1. Patient/subject groups
We conducted a cross-sectional study of Caucasian pa-
tients with MCI and AD compared with cognitively healthy
age- and gender-matched controls recruited consecutively
from the Neurology and Ophthalmology departments of
the University Hospital Marques de Valdecilla (UHMV), be-
tween May 2016 and June 2018. HCs were matched with
MCI and AD separately and with both groups together.
Indeed, AD and MCI were compared.
HCs were volunteers recruited among the family mem-
bers of patients attending the ophthalmology clinic with a
complaint of dry eye. They were n’ot screened with neuro-
psychological tests or 11C-PiB PET/CT.
The study protocol was approved by the Ethics Commit-
tee of the UHMV, and it was performed in accordance with
the principles of the Declaration of Helsinki. Written con-
sent forms were signed by all participants before the exam-
inations.
2.2. Inclusion and exclusion criteria
All patients met research diagnostic criteria for AD and
MCI [20]. Cases were confirmed in the neurology clinic as
part of the Valdecilla Cohort for Memory and Brain Aging,
a prospective study to evaluate early disease changes in non-
demented individuals. Patients older than 55 years with a
classic (amnesic) clinical presentation of AD or MCI and
positive 11C-PiB PET/CT scan were recruited. Diagnoses
were established by a clinical committee of four neurologists
(S.L.-G., P.S.-J., E.R.-R., and C.L.) and two neuropsycholo-
gists (A.P., M.G.-M.). All patients were assessed by a multi-
disciplinary team to exclude other neurological or
psychiatric etiologies. Structural neuroimaging with CT or
MRI was performed. All participants underwent a compre-
hensive neuropsychological battery conducted by two
trained neuropsychologists (A.P., M.G.-M.), that included
the main cognitive domains (memory, language, praxis, vi-
sual perception, and frontal functions). All patients under-
went 11C-PiB PET/CT at the Nuclear Medicine
Department of the UHMV. 11C-PiB synthesis and image
acquisition have been described elsewhere [21]. PET/CT
scans were visually interpreted by two experienced nuclear
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cortical PiB uptake.
Exclusion criteria included a refractive error .6.0 diop-
ters (D) of spherical equivalent or 3.0 D of astigmatism,
any history of ocular surgery, ocular disease, best-corrected
visual acuity as poor as 20/40, intraocular pressure
(IOP)  18 mm Hg, past history of raised IOP, neuroretinal
rim notching, or optic disc hemorrhages. Similarly, other
exclusion criteria included clinically relevant opacities of
the optic media and low-quality images due to unstable fixa-
tion, or severe cataract (patients with mild to moderate cata-
ract might be enrolled in the study, but only high-quality
images were included). Subjects with a history of neurolog-
ical or psychiatric disorder, any significant systemic illness,
poor collaboration due to neurological dementia stage or un-
stable medical condition (e.g., active cardiovascular dis-
ease), and current use of any medications known to affect
cognition (e.g., use of sedative narcotics) were also excluded.2.3. Ophthalmic assessment
All subjects underwent a thorough ophthalmic examina-
tion on the day of OCT imaging, including best-corrected vi-
sual acuity (Snellen charts), refraction, IOP measurement
with Goldmann applanation tonometer, anterior segment
biomicroscopy, and dilated fundus examination. The refrac-
tive error was recorded using an Autorefractometer Canon
RK-F1 (Canon USA Inc., Lake Success, NY, USA). Axial
length was measured by Lenstar LS 900 (Haag-Streit AG,
K€oniz, Switzerland).
Each patient was randomized to decide which eye was to
be examined first, using themethod described by Dulku [22].2.4. Optical coherence tomography imaging
A single, well-trained ophthalmologist (A.C.), who was
masked to the diagnosis of the patients, performed all
OCT examinations. Participants received one drop of tropi-
camide 1% and phenylephrine per eye for pupil dilation
before OCT imaging.
Retinal thickness was measured with spectral-domain
(SD) Spectralis SD-OCT (Heidelberg Engineering, Heidel-
berg, Germany) using the images obtained by posterior
pole analysis scan. Using this protocol, the OCT instrument
automatically delineates a line joining the center of the fovea
and the center of the optic disc as a reference line. There-
upon, 61-line scans (1024 A scans/line) parallel to the cen-
tral reference line are recorded. The quality of the scans is
indicated on a color scale at the bottom of the scanned im-
ages. Only scans in the green range were considered of suf-
ficiently good quality for inclusion in this study. The
automatic real-time tracking of these scans was 25. A
masked investigator (A.L.-de-E.) examined all images of
each eye to identify any segmentation or centered errors in
the images. The average retinal layer measurement of each
3 x 3 sector was determined, which made up the 4 sectors(superior, temporal, inferior, and nasal). Segmentation anal-
ysis was performed using Heidelberg segmentation software
(version 1.10.2.0) to calculate thickness of the GCL, inner
plexiform layer (IPL), and outer nuclear layer (ONL)
(Fig. 1A) considering APOSTEL recommendations [23].
The new GMP Edition provided by Spectralis 6.0c
version was used, including 24 radial and 3 circular scans.
BMO-based MRW is automatically centered at the optic
nerve head, and 24 radial B-scans were acquired over a
15 area. The shortest distance from each identified BMO
point to the internal limiting membrane (Fig. 1B) was
measured. After image acquisition, the BMO segmentation
was reviewed and confirmed by a trained examiner (A.C.).
RNFL thickness measurements of each individual eye
were normalized for anatomic orientation of the fovea to op-
tic nerve to an accurate and consistent positioning of the
RNFL thickness measurement across eyes (automatic real-
time tracking mean 100). Although the newmodule includes
3 circle scans (inner circle: 3.5 mm, middle circle: 4.1 mm,
and outer circle: 4.7 mm), we registered only the figures pro-
vided by the inner circle scan (standard) (Fig. 1C). Six sector
areas (superotemporal, superior, superonasal, inferonasal,
inferior, and inferotemporal) and the average were measured
in both analyses.
LC was measured by performing one vertical scan closest
to the optic nerve head center, at the point where the visibility
of the anterior LC surface was as complete as possible, by
excluding the main vessels using enhanced depth image tech-
nology, with an average of over 100 scans using the automatic
averaging mode. A reference line connecting the two Bruch’s
membrane end points was drawn, and three equidistant points
(inferior, middle, and superior), corresponding to one-third
and one-half of this reference, were matched to the anterior
prelaminar tissue surface and anterior LC surface (Fig. 1D).
Prelaminar tissue thickness (PTT) and anterior LC surface
depth were measured at the three aforementioned points.
PTTwas defined as the distance between the anterior prelami-
nar tissue surface and anterior LC surface. Anterior LC sur-
face depth was determined by measuring the distance from
the reference line to the level of the anterior LC surface. Mea-
surements were made using the SPECTRALIS software
manual caliper tool by the aforementioned masked investiga-
tors (A.L.-de-E., A.C.).2.5. Statistical analysis
Student’s t-test for dependent samples was used to
compare RNFL, BMO-MRW, and GCL between patients
with AD and healthy gender- and age-matched controls.
The intraclass correlation coefficient (ICC) was used to eval-
uate interobserver reproducibility in LC measurements and
consequently the reliability of the results of the measure-
ments that were manually quantified.
A receiver operating characteristic curve was used to
assess the discrimination value of the OCT analyses. We
used the area under the receiver operating characteristic
Fig. 1. A representation of retinal layers and optic nerve changes that could be depicted in AD by optical coherence tomography (OCT) in a 67-year-old man.
The software automatically marked the following layers in a single horizontal foveal scan: (A) ganglion cell layer (GCL) analysis showing a diffuse decrease in
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Table 1
Demographic and clinical participant’s characteristics (63 eyes of 34
individuals)
Variables Patients (N 5 63) Controls (N 5 63) P
Age (years) 73.5 (6.0) 73.28 (6.0) .998
Male eyes (%) 31 (49.2) 31 (49.2) 1
Spherical equivalent
(Diopters)
0.53 (1.10) 0.58 (1.22) .797
BCVA 20/29 (0.34) 20/26 (0.17) .259
Axial length (mm) 23.2 (0.8) 23.2 (0.9) .816
IOP 13.7 (3.9) 12.8 (2.8) .154
=
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nesses to discriminate AD, MCI, and AD/MCI from HC
[24]. All statistical analyses were performed using IBM
SPSS Statistics V.20.0 (International Business Machine Cor-
poration, Armonk, NY, USA).
2.6. Data availability
All data generated or analyzed during this study are
included in the main manuscript and its supplementary infor-
mation files.NOTE. Data for quantitative variables are shown as mean (standard devi-
ation).
Sex differences were assessed with Fisher’s test. Rest of analysis was per-
formed using paired Student’s t-test for dependent samples. Patients means
mild cognitive impairment (MCI) and Alzheimer’s disease (AD) patients
altogether.
Abbreviations: BCVA, best-corrected visual acuity; IOP, intraocular pres-
sure.3. Results
In total, 51 MCI eyes and 12 AD eyes from 34 patients,
and 63 eyes from 32 HCs were included in the final analysis
on the basis of inclusion and exclusion criteria. Five
PiB1 eyes were omitted because of poor collaboration.
The demographic and clinical characteristics of patients
with AD and controls showed no significant differences be-
tween both groups, see Table 1. Mean age was
73.56 6.0 years (age range: 57–85 years). All eyes included
were phakic.
Table 2 shows the relationship of RNFL, BMO-MRW,
ONL, IPL, and GCL with PiB1, MCI, AD, and the cogni-
tively healthy control group (HC).
GCL thickness showed a significant reduction across the
MCI group in the temporal sector compared with the HC group
(42.26 8.4 mm in MCI and 46.16 6.1 mm in HC; P5 .015).
Compared with HCs, patients with AD had GCL thickness
reduction significantly in the superior sector (44.3 6 14.9 mm
in AD and 55.2 6 5.4 mm in HC; P 5 .050). More significant
differences were identified when both groups (MCI and AD)
were compared with controls, including significant thinning of
GCL in all locations (P , .014).
IPL was significantly reduced in the superior and nasal re-
gions in the PiB1 group (P 5 .011 and P 5 .025, respec-
tively) and in all superior, inferior, temporal, and nasal
sectors in the AD group (P 5 .026, P 5 .007, P 5 .044,
P5 .009; respectively), whereas the results in theMCI group
were not significant.
ONL showed significant changes in the superior sector in
the MCI group (63.36 11.6 mm in MCI and 68.16 11.3 mm
in HC; P 5 .048) and in the PiB1 group (P 5 .010).
Average RNFL thickness and temporal-inferior quadrant
and temporal quadrant RNFL thickness were significantly
reduced in MCI compared with control eyes (P 5 .005,
P 5 .018, P 5 .050; respectively). Once more, the compari-
son between the PiB1 group (MCI and AD subjects) and
control eyes supports the aforementioned outcomes, but
with greater statistical power (average RNFL P5 .004, tem-
poral P5 .028, temporal inferior P5 .004) and provides newall sectors, (B) reduced inner plexiform layer (IPL) thicknesses, and (C) outer nu
width (BMO-MRW) showing neither diffuse damage nor sector decrease. (E)
RNFL thinning is supported, due in particular to temporal sector damage. (F) Th
next to the optic nerve head center, is not damaged. Abbreviation: AD, Alzheimeinformation with regard to a significant thinning of temporal
superior sector RNFL (P 5 .019).
Average BMO-MRW was significantly reduced in MCI
(P 5 .027) and also thinner in PiB1 subjects
(290.3 6 54.1 mm) than in HCs (303.5 6 54.6 mm). Never-
theless, no statistical significance was found in the latter
group or in average BMO-MRW (P 5 .263), even when
the 6 BMO-MRW sectors were compared (P . .131).
The study revealed no statistically significant differences
in LC parameters between the PiB1 and control group.
ICCs were 0.974, 0.993, and 0.978 for superior, central,
and inferior LC surface depth, respectively. Similarly,
ICCs were .0.992 for PTT measurements, as depicted in
Table 3.
We also analyzed OCT results comparing MCI and AD
subjects (see Table 4). Although no significant differences
were found, the measurements tended to be thinner in the
AD group than in the MCI group, GCL in particular.
Table 5 shows the receiver operating characteristic AUC
analysis of different OCT measurements with 95% confi-
dence limits for sensitivity and specificity. Higher AUC
values correlating with a diagnosis of MCI were observed
for average, temporal, and temporal superior RNFL
(0.652, 0.660, and 0.666; respectively) and temporal sector
GCL (0.699).4. Discussion
In vivo anatomical studies have provided further evidence
of direct involvement of the retina, choroid, and optic nerve
head in patients with AD [12]. For this reason, we used SD-
OCT to compare RNFL, GCL, LC, and rim analysis between
patients with brain amyloid accumulation PiB1 (MCI andclear layer (ONL) thinning. (D) Bruch’s membrane opening–minimum rim
Reduced retinal nerve fiber layer (RNFL) thickness; in this case, diffuse
e anterior surface of the lamina cribrosa (LC), performed by vertical scan
r’s disease.
Table 2
Comparison of different optical coherence tomography analysis between patients and control eyes; mild cognitive impairment (MCI) patients and control eyes





(N 5 63) P MCI (N 5 51)
Controls
(N 5 51) P AD (N 5 12)
Controls
(N 5 12) P
Average RNFL thickness 97.7 (11,6) 99.9 (8.2) .004* 93.7 (12.5) 99.5 (8.1) .005* 99.4 (5.1) 102.0 (9.3) .482
RNFL temporal 66.5 (9.0) 71.3 (10.2) .028* 65.9 (9.4) 70.9 (10.7) .050* 70.0 (6.2) 74.1 (5.8) .312
RNFL temporal-superior 118.8 (16.6) 127.4 (17.4) .019* 119.5 (16.3) 127.3 (17.3) .062 115.0 (19.0) 128.3 (19.1) .080
RNFL temporal-inferior 139.4 (20.8) 149.8 (15.8) .004* 139.5 (22.0) 149.0 (15.1) .018* 138.7 (10.4) 153.7 (19.6) .062
RNFL nasal 80.5 (17.8) 81.7 (15.2) .673 79.6 (18.3) 80.1 (15.5) .875 85.2 (14.4) 90.4 (10.5) .386
RNFL nasal-superior 111.3 (22.6) 117.3 (25.8) .201 108.9 (22.1) 117.4 (25.5) .090 124.3 (22.1) 166.6 (20.1) .571
RNFL nasal-inferior 105.5 (29.6) 114.0 (18.0) .062 109.7 (27.4) 114.5 (16.8) .275 83.0 (33.1) 111.4 (24.9) .100
Average BMO-MRW 290.3 (54.1) 303.5 (54.6) .263 281.9 (49.9) 309.4 (54.9) .027* 326.8 (58.8) 278.8 (47.3) .106
BMO-MRW temporal 208.9 (49.9) 203.3 (43.5) .649 207.7 (52.8) 205.4 (46.1) .878 214.2 (27.6) 193.8 (30.5) .012*
BMO-MRW temporal-superior 272.4 (64.2) 291.9 (49.8) .231 272.2 (70.1) 295.2 (53.6) .240 273.3 (28.8) 276.8 (24.7) .848
BMO-MRW temporal-inferior 286.2 (67.5) 315.6 (64.6) .131 277.6 (69.7) 317.4 (64.9) .091 324.6 (41.2) 307.6 (68.8) .267
BMO-MRW nasal 319.8 (65.5) 325.2 (60.4) .735 305.5 (55.2) 327.3 (61.7) .202 383.6 (74.9) 315.5 (58.7) .095
BMO-MRW nasal-superior 328.0 (75.0) 347.2 (54.7) .323 322.4 (74.9) 348.1 (53.2) .237 353.0 (76.3) 343.3 (66.5) .845
BMO-MRW nasal-inferior 348.3 (63.6) 371.0 (59.1) .138 342.2 (61.8) 372.6 (61.3) .089 375.6 (69.8) 363.8 (52.0) .657
GCL superior 47.5 (9.1) 51.8 (5.6) .006* 48.3 (7.1) 51.0 (5.5) .057 44.3 (14.9) 55.2 (5.4) .050*
GCL inferior 46.5 (9.8) 50.9 (6.0) .008* 47.1 (8.5) 50.2 (6.1) .052 44.2 (14.4) 53.7 (4.5) .078
GCL temporal 41.7 (9.5) 46.7 (5.8) .002* 42.2 (8.4) 46.1 (6.1) .015* 39.6 (13.4) 49.1 (4.3) .074
GCL nasal 46.5 (9.3) 50.5 (6.4) .014* 47.3 (7.8) 50.1 (6.6) .089 43.3 (14.2) 52.7 (5.1) .078
IPL superior 39.0 (4.3) 41.1 (3.6) .011* 39.1 (4.4) 40.5 (3.2) .097 38.8 (4.1) 44.0 (3.9) .026*
IPL inferior 38.6 (4.3) 40.1 (3.7) .066 38.5 (4.5) 39.6 (3.7) .268 38.8 (2.9) 42.4 (2.5) .007*
IPL temporal 39.6 (4.1) 40.8 (3.6) .111 39.6 (4.1) 40.3 (3.3) .421 39.2 (3.8) 43.0 (4.1) .044*
IPL nasal 39.8 (3.9) 41.4 (3.5) .025* 39.7 (4.1) 41.0 (3.4) .138 39.7 (3.3) 43.3 (3.0) .009*
ONL superior 63.4 (11.7) 68.9 (10.7) .010* 63.3 (11.6) 68.1 (11.3) .048* 63.5 (12.3) 72.7 (5.8) .058
ONL inferior 60.7 (15.2) 63.5 (12.2) .344 60.3 (14.5) 63.5 (12.7) .296 62.5 (18.4) 63.1 (10.0) .947
ONL temporal 69.4 (10.2) 72.7 (10.3) .072 68.6 (10.5) 72.2 (10.8) .100 72.9 (7.8) 75.0 (6.7) .442
ONL nasal 68.3 (15.3) 72.2 (11.8) .156 68.2 (15.1) 72.2 (11.6) .166 68.3 (16.9) 72.0 (13.2) .676
NOTE. Data for quantitative variables are shown as mean (standard deviation). Analysis was performed using paired Student’s t-test for dependent samples.
Patients means mild cognitive impairment (MCI) and Alzheimer disease (AD) patients altogether.
Abbreviations: RNFL, retinal nerve fiber layer; GCL, ganglion cell layer; BMO-MRW, Bruch’s membrane opening–minimum rim width; IPL. inner plex-
iform layer; ONL, outer nuclear layer.
*P value , .005.
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tients with detailed neurocognitive testing and PET imaging
with 11C-PiB ligand analysis that could readily differentiate
between participants with normal cognition from dementia
due to AD, as previously reported [6,7]. PiB imaging has
many potential clinical benefits, such as preclinical
detection of AD and an accurate differentiation of AD
from dementias of other etiologies.
In our study, RNFL and GCLwere significantly thinner in
MCI and AD subjects compared with HC assessed by SD-
OCT. Our results strongly suggest that retinal ganglion cells
and optic nerve axonal damage can be clinically detected in
prodromal AD.
Several studies have previously reported a significant
decrease in mean overall RNFL thickness in patients with
AD, generating interest in the use of this parameter as a
biomarker for early detection of AD. Initially, evidence of
average RNFL thinning in patients with AD was demon-
strated with time domain OCT [17,25] and has
subsequently been confirmed by several independent
groups using various modern OCT devices, such as
spectral-domain (SD) OCT [14–16,26,27]. Findings were
supported by three meta-analyses [26,28]. Differences inthe most affected peripapillary quadrants, such as superior
sector RNFL [19,29] and both superior and inferior sector
RNFL [29], were later reported. Our findings agreed with
previous clinical studies that reported a lower average
RNFL in the PiB1 group, particularly in the superior and
inferior quadrant, compared with HC.
However, den Haan et al. [30] have recently reported that
neither macular nor RNFL thicknesses are reduced in pa-
tients with AD. We believe that this might be due to the
exclusion criteria used by these authors, as they excluded pa-
tients with optic nerve anomalies assessed with Heidelberg
Retinal Tomography, to avoid enrolling patients with glau-
coma. However, patients with optic nerve damage due to
AD may also have been ruled out by these criteria. The cri-
terion we used to exclude patients with glaucoma was IOP
.18 mm Hg or patients receiving glaucoma treatment,
similar to other publications [27,30,31].
Average RNFL reduction was recently shown not only in
AD subjects but also in MCI compared with controls, and
some authors found that RNFL thickness was significantly
lower in AD than MCI [32], whereas other groups did not
observe statistical significantly differences between MCI
and AD patients [17,33]. In our study, we found no
Table 4
Comparison of different optical coherence tomography analysis between
mild cognitive impairment (MCI) and Alzheimer’s disease (AD) eyes
Variables MCI (N 5 51) AD (N 5 12) P
Average RNFL thickness 93.7 (12.5) 99.4 (5.1) .155
RNFL temporal 65.9 (9.4) 70.0 (6.2) .411
RNFL temporal-superior 119.5 (16.3) 115.0 (19.0) .793
RNFL temporal-inferior 139.5 (22.0) 138.7 (10.4) .774
RNFL nasal 79.6 (18.3) 85.2 (14.4) .653
RNFL nasal-superior 108.9 (22.1) 124.3 (22.1) .060
RNFL nasal-inferior 109.7 (27.4) 83.0 (33.71) .045*
Average BMO-MRW 281.9 (49.9) 326.8 (58.8) .016*
BMO-MRW temporal 207.7 (52.8) 214.2 (27.6) .740
BMO-MRW temporal-superior 272.2 (70.1) 273.3 (28.8) .984
BMO-MRW temporal-inferior 277.6 (69.7) 324.6 (41.2) .126
BMO-MRW nasal 305.5 (55.2) 383.6 (74.9) .006*
BMO-MRW nasal-superior 322.4 (74.9) 353.0 (76.3) .392
BMO-MRW nasal-inferior 342.2 (61.8) 375.6 (69.8) .245
GCL superior 48.3 (7.1) 44.3 (14.9) .174
GCL inferior 47.1 (8.5) 44.2 (14.4) .365
GCL temporal 42.2 (8.4) 39.6 (13.4) .384
GCL nasal 47.3 (7.8) 43.3 (14.2) .185
IPL superior 39.1 (4.4) 38.8 (4.1) .852
IPL inferior 38.5 (4.5) 38.8 (2.9) .890
IPL temporal 39.6 (4.1) 39.2 (3.8) .740
IPL nasal 39.7 (4.1) 39.7 (3.3) .944
ONL superior 63.3 (11.6) 63.5 (12.3) .086
ONL inferior 60.3 (14.5) 62.5 (18.4) .652
ONL temporal 68.6 (10.5) 72.9 (7.8) .203
ONL nasal 68.2 (15.1) 68.3 (16.9) .923
NOTE. Data for quantitative variables are shown as mean (standard devi-
ation). Analysis was performed using paired Student’s t-test for dependent
samples.
Abbreviations: RNFL, retinal nerve fiber layer; GCL, ganglion cell layer;
BMO-MRW, Bruch’s membrane opening–minimum rim width; IPL, inner
plexiform layer; ONL, outer nuclear layer.
*P value , .005.
Table 3
Intraclass correlation coefficient (ICC) used to determine interobserver








Abbreviations: S, superior; I, inferior; PTT, prelaminar tissue thickness;
LCD, anterior LC surface depth.
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interestingly, the study revealed GCL reduction in all
sectors in AD compared to MCI, supporting the idea of
correlation between the duration of the disease and
macular thinning and optic nerve disease.
If optic nerve damage, displayed as RNFL thinning, is
assumed in PiB1 patients and might begin there, we hypoth-
esized that BMO-MRW or LC optic nerve structures should
be thinned in those patients. In glaucoma, OCT-derived
BMO-MRWanalysis provides significantly greater sensitivity
[34] and specificity [19] than RNFL, so by this argument, we
presumed that BMO-MRWanalysis might also be more sen-
sitive in assessing optic nerve damage in AD.We found a sig-
nificant reduction in average BMO-MRW in the MCI group
compared with HC, but no significant thinning was described
either in PiB1 or in AD patients compared with HC. Simi-
larly, we found no significant reductions in LC thickness.
We therefore presume that ocular damage might start in
the GCL [35]. Macular GCL-IPL reflects the thickness of
retinal ganglion cell bodies and dendrites in the retina. In
1986, Hinton et al. [13] provided histopathological evidence
of optic neuropathy and degeneration of retinal ganglion
cells in AD subjects, and later, in a postmortem study, sub-
stantial GCL degeneration was demonstrated in the foveal/
parafoveal region in AD. OCT imaging in vivo first showed
decreased total macular thickness in AD subjects [16,31]
and later, when macular segmentation was available,
Marziani et al. reported significant reductions in combined
RNFL and GCL thickness (RNFL1GCL1IPL) in the
macular region [15]. Nevertheless, Cheung et al. [33] sug-
gested that including the RNFL in the GCL analysis in the
macular area may influence the sensitivity for revealing
GCL abnormalities, so they measured GCL-IPL without
including the RNFL and found significant GCL-IPL thin-
ning in AD and MCI patients compared with HC. In accor-
dance with the latest reviews, our study revealed that
PiB1 patients had significant GCL thickness reduction,
mainly in the temporal sector (P, .014) and adds the knowl-
edge that GCL is more affected by thinning than RNFL in
MCI subjects. We also found significant IPL thinning in
all sectors in AD subjects compared with HC.
Recently, Koronyo et al. [36] described classic plaques of
extracellular Ab deposits in the retina of patients with ADin vitro and marked GCL, INL, and ONL loss in the retinas
of patients with AD compared with retinas of matched con-
trols. Our results reflect these findings, as we found significant
GCL thinning in the four sectors. On the contrary, some
in vivo studies displayed controversial GCL measurements
using SD-OCT, reporting that RNFL and GCL thickness
were unable to distinguish AD dementia from MCI and
normal controls in clinically well-characterized series
[37,38]. The authors themselves hypothesized that a larger
series would be necessary to delineate significant
differences between the groups studied. In our opinion, their
study has methodological limitations. Although PET
imaging was performed as an inclusion criterion for AD,
neither the ligand used nor the imaging result are detailed.
Furthermore, patients with glaucoma were excluded, but the
criteria for exclusion are not clearly or correctly described.
Our study has several limitations. The number of patients
is small and the design is cross-sectional. Future studies
should include more subjects with early-stage AD and
late-stage AD, longitudinal measurements, and disease-
specific imaging aimed at detecting retinal amyloid. Corre-
lation with volumetric MRI data (e.g., hippocampus, optical
Table 5
Area under the curve (AUC) of the receiver operating characteristic curve
(ROC)
Variables AUC P
Average RNFL thickness .652 .015
RNFL Temporal .660 .010
RNFL Temporal-superior .666 .008
RNFL Temporal-inferior .641 .024
RNFL Nasal .554 .382
RNFL Nasal-superior .570 .264
RNFL Nasal-inferior .488 .844
Average BMO-MRW .616 .063
GCL superior .668 .007
GCL inferior .677 .005
GCL temporal .699 .001
GCL nasal .660 .010
IPL superior .666 .008
IPL inferior .629 .039
IPL temporal .612 .072
IPL nasal .662 .010
ONL superior .668 .007
ONL inferior .554 .369
ONL temporal .670 .006
ONL nasal .539 .634
NOTE. Analysis with 95% confidence limits for sensitivity and speci-
ficity of different optical coherence tomography parameter analysis in
mild cognitive impairment (MCI).
Bold values represent the high AUC result.
Abbreviations: RNFL, retinal nerve fiber layer; GCL, ganglion cell layer;
BMO-MRW, Bruch’s membrane opening–minimum rim width; IPL, inter
plexiform layer; ONL, outer nuclear layer.
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relationship between retinal and cerebral neuronal loss.
Furthermore, one single vertical optical nerve head scan
was selected for the morphometric analysis, whereas the re-
maining peripheral scans were not evaluated. However, only
the highest-quality images and the most centered vertical
scan without retinal vasculature, in which borders were
more clearly visible, were evaluated. Finally, LC thickness
was not evaluated because the contour delineation of the
posterior LC surface was broadly less accurate than the other
structures.
A potential strength of the study is that the research pro-
tocol was undertaken in a real clinical setting, so observa-
tions from the present study very likely represent day-to-
day clinical practice.
This study confirmed RNFL and GCL damage in AD and
MCI patients (enrolled with 11C-PiB measurement) leading
us to hypothesize that retinal damage is due to Ab deposition
within the retina. It is interestingly reported that macular
GCL neuronal loss is more strongly related with MCI than
RNFL loss, suggesting that RNFL thinning may not occur
until severe stages of AD as a consequence of GCL loss in
the macula due to a dense population of those cells in this re-
gion. However, more evidence of RNFL thinning in patients
with AD exists in the literature, but this might be because
RNFL analysis was available before GCL measurement.
Larger, longitudinal studies comparing retinal thickness
with biomarkers for amyloid and neuronal injury arerequired to elucidate the utility of retinal and optic nerve
thickness as a screening test and/or prognostic biomarker
in early-onset AD.
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1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed). Although
several studies using optical coherence tomography
(OCT) to analyze eye structures have reported retinal
and optic nerve changes in Alzheimer’s disease
(AD), to the best of our knowledge, this might be
the first report that analyzes OCT changes in individ-
uals with cognitive impairment and positive 11C-PiB
PET/CT. Even more, this study assessed lamina cri-
brosa and Bruch’s membrane opening–minimum
rim width in patients with AD.
2. Interpretation: Our findings confirm OCT damage in
patients with AD and led to an integrated hypothesis
describing the pathophysiology of AD.
3. Future directions: The article hypothesizes that
retinal damage is due to Ab deposition within the
retina and proposes a framework for the generation
of new hypotheses and the conduct of additional
studies. It is interestingly reported that macular
neuronal loss is more strongly related with early
AD than retinal nerve fiber layer loss.References
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